ASCO Conference Highlights: Metastatic Colorectal Cancer, Bladder Cancer

Olympia Trial - PARP inhibitors demonstrated activity in multiple cancers which are related to BRCA mutations. AstraZeneca’s Lynparza (olaparib), one such PARP inhibitor, is indicated for various advanced cancer types. Lynparza label was approved in 2017, for the treatment of patients with germline BRCA-mutated (gBRCAm), HER2-negative metastatic breast cancer previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting, it is still not approved for use in high-risk HER2 negative early breast cancer with gBRCAm.

The Olympia trial study evaluated Lynparza in patients with gBRCA1/2 mutated HER2 negative early breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy. Olympia trial results were based on a randomized, double-blind, parallel-group, placebo-controlled multicenter Phase III trial, which, once complete, can provide Lynparza with the commercial opportunity in the adjuvant setting.

As per MSD the analysis of the Olympia trial breast cancer study, based upon the IDMC recommendation, could be able to represent a potential step forward for patients with early-stage, high-risk primary breast cancer with a germline BRCA mutation. Thus, the successful attainment of primary endpoints makes Olympiad Lynparza the first PARP inhibitor to demonstrate clinical benefit as an adjuvant treatment in early breast cancer.

Check in-depth Information- Olympia Lynparza